SCHEMBL3333497

SCHEMBL3333497

N[C@@H]1COCC(=O)N1Cc1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 3/20 0.46
EHMT2 Q96KQ7 1/20 0.44
HCRTR1 O43613 1/20 0.40
HCRTR2 O43614 1/20 0.40
CYP2C19 P33261 3/20 0.39
ALDH1A1 P00352 3/20 0.39
CYP2C9 P11712 2/20 0.39
HPGD P15428 2/20 0.39
CYP3A4 P08684 2/20 0.39
CYP1A2 P05177 1/20 0.39
GAA P10253 1/20 0.39
STAT6 P42226 1/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
GSK3A P49840 2/20 0.38
GSK3B P49841 2/20 0.38
TSHR P16473 2/20 0.38
F2 P00734 1/20 0.38
PLG P00747 1/20 0.38
ELANE P08246 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1008150 0.81 P2RX7 (0.46) P2RX7EHMT2HCRTR1HCRTR2MEN1
SCHEMBL1008151 0.81 P2RX7 (0.46) P2RX7EHMT2HCRTR1HCRTR2MEN1
SCHEMBL1189963 0.81 P2RX7 (0.46) P2RX7EHMT2HCRTR1HCRTR2MEN1
SCHEMBL6852820 0.80 P2RX7 (0.46) P2RX7EHMT2HCRTR1HCRTR2CYP2C19
SCHEMBL3333492 0.80 P2RX7 (0.56) P2RX7EHMT2HCRTR1HCRTR2CYP2C19
SCHEMBL6133226 0.79 P2RX7 (0.45) P2RX7EHMT2HCRTR1HCRTR2ALDH1A1
SCHEMBL1190522 0.79 P2RX7 (0.58) P2RX7EHMT2HCRTR1HCRTR2CYP2C19
SCHEMBL12018713 0.79 P2RX7 (0.46) P2RX7EHMT2HCRTR1HCRTR2CYP2C19
SCHEMBL10215486 0.79 P2RX7 (0.47) P2RX7EHMT2HCRTR1HCRTR2CYP2C19
SCHEMBL12495007 0.79 P2RX7 (0.47) P2RX7EHMT2HCRTR1HCRTR2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100144727-A1 Oxazolidine and Morpholine Carboxamide Derivatives as P2X7 Modulators BESWICK PAUL JOHN 2010-06-10 US disclosed
EP-2139875-A2 OXAZOLIDINE AND MORPHOLINE CARBOXAMIDE DERIVATIVES AS P2X7 MODULATORS Glaxo Group Limited (GB) 2010-01-06 EP disclosed
WO-2008119685-A2 OXAZOLIDINE AND MORPHOLINE CARBOXAMIDE DERIVATIVES AS P2X7 MODULATORS GLAXO GROUP LIMITED (GB) 2008-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144727-A1 Oxazolidine and Morpholine Carboxamide Derivatives as P2X7 Modulators P2RX5, P2RX3, P2RX7 P2RX7 3/4885EHMT2 4388/4885HCRTR1 129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.